Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Once Safety Issues Are Addressed, Rx Importation "Makes Sense," President Bush Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Outstanding safety concerns are the sole reason for not yet allowing reimportation from Canada, Bush says during Q&A session with voters. By making drug imports a question of resources, he opens the door to approving some version of the practice.

Related Content

Rx Imports: President Bush Says Decision Could Come In December
FDA Wants Broad Reimportation Enforcement Discretion
Lawmakers "Don't Care" About Safety Concerns With Rx Imports - GSK
Reimportation Law Unlikely This Year Despite Democratic Pressure
Medicare Rx Hearings Planned For Senate Committee On Aging
Illinois Reimportation Plan Includes EU Countries, Role For PBM
Rx Imports Will Be Allowed By Bush Administration, Former CMS Head Says
PhRMA Braces For Reimportation Fight; Job "Outsourcing" Is New Argument
PhRMA Braces For Reimportation Fight; Job "Outsourcing" Is New Argument
Rx Import Bill Could Be Modeled On Food Inspection Program – McClellan





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts